Marcel Miron-Celis: The Largest Cohort Ever Studied on Perioperative Management of Thrombotic APS
Marcel Miron-Celis, Data Scientist at MDClone, shared Joseph R. Shaw‘s post on LinkedIn, adding:
“If you are a physician interested in the perioperative management of patients with thrombotic antiphospholipid syndrome, then you should read this awesome research paper that I worked on with my previous colleagues at The Ottawa Hospital.
Largest cohort ever studied on this topic, with very interesting findings!”
Joseph R. Shaw, Director of Research and Program at Ottawa Department of Medicine, EHJ-CVP Associate Editor of European Heart Journal, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Advances, adding:
”I’m pleased to share that our paper, ‘Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome,’ has been published in Blood Advances.
This project grew out of a practical and difficult question we face often in thrombosis care: how should we manage anticoagulation interruption in patients with thrombotic APS who need surgery or an invasive procedure?
Data to guide these decisions is limited.
In this study, we evaluated 172 adults with thrombotic APS who underwent 282 planned perioperative anticoagulation interruptions between 2016 and 2025.
To our knowledge, this is the largest single-center cohort focused on perioperative anticoagulation management in thrombotic APS.
A few key findings stood out to me:
- Bridging was commonly used, and clinicians appeared to individualize management based on APS phenotype and prior thrombotic history.
- Patients with triple-positive APS and those with prior arterial thromboembolism were more likely to receive therapeutic-dose LMWH bridging.
Overall, 30-day outcomes were reassuring: the risks of arterial thromboembolism and major bleeding were both 0.7%, while clinically relevant nonmajor bleeding occurred in 3.2% of interruptions.
The take-home message: individualized, risk-adapted perioperative anticoagulation management that considers APS-related thrombotic risk, procedural bleeding risk, and clinical context appears feasible and safe in thrombotic APS.
At the same time, high-risk phenotypes – especially triple-positive APS and prior arterial events – still require careful planning and vigilance.
A special congratulations to Miguel Paquette.
This paper reflects his hard work, persistence, and attention to detail, and I’m very glad to see these important results published in Blood Advances.”
Title: Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome
Authors: Miguel Paquette, Sébastien Miranda, Yan Xu, Leslie Skeith, Marcel Miron-Celis, Ronald A. Booth, Hakan Buyukdere, Deborah M. Siegal, Grégoire Le Gal, Marc Carrier, James D. Douketis, Jerrold H. Levy, Jean M. Connors, Aurélien Delluc, Joseph R. Shaw

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?
-
Nov 17, 2026, 23:33Remi Remakanth: The Role of Transfusion Medicine in HLA Antibody Testing and Transplant Desensitization